Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Aug 23;146(8):652-654.
doi: 10.1161/CIRCULATIONAHA.121.058294. Epub 2022 Aug 22.

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

Francesco Cosentino  1 , Christopher P Cannon  2 , Robert Frederich  3 , David Z I Cherney  4 , Samuel Dagogo-Jack  5 , Richard E Pratley  6 , James P Mancuso  7 , Mario Maldonado  8 , Nilo B Cater  9 , Shuai Wang  7   10 , Darren K McGuire  9
Affiliations
Clinical Trial

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

Francesco Cosentino et al. Circulation. .
No abstract available

Keywords: cardiovascular diseases; diabetes mellitus, type 2; metformin; sodium-glucose transporter 2 inhibitors.

PubMed Disclaimer

Figures

Figure.
Figure.
Cardiovascular and kidney outcomes with ertugliflozin versus placebo by baseline metformin use after propensity adjustment for metformin use. Differences in risk of cardiovascular and kidney outcomes between ertugliflozin and placebo across subgroups by baseline metformin use were estimated from a Cox proportional hazards model by means of propensity adjustment for metformin use by using inverse probability of treatment weighting to account for differences in baseline characteristics and risk factor profiles between patients with and without baseline metformin use. Treatment, baseline metformin use, and the interaction term between treatment and baseline metformin use were included in each model, and the enrollment cohort was included as a stratification factor. Model weights were calculated using propensity score estimates of baseline metformin use and the inverse probability of treatment weighting formula. The variables considered in propensity scoring were age, sex, race, region, body mass index, duration of type 2 diabetes, glycated hemoglobin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate, and history of: coronary artery disease, cerebrovascular disease, peripheral arterial disease, heart failure, myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, and stroke. Hazard ratios (95% CIs) are provided for ertugliflozin versus placebo by baseline metformin use. The interaction P value is shown for the 2-level treatment group (all ertugliflozin versus placebo). The kidney composite outcomes were doubling of serum creatinine level, kidney replacement therapy, or death from kidney causes and the exploratory kidney outcome of sustained ≥40% decrease in eGFR from baseline, kidney replacement therapy, or death from kidney causes. BL indicates baseline; Cr, creatinine; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; and MACE, major adverse cardiovascular events.
See this image and copyright information in PMC

References

    1. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al.. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486 - PubMed
    1. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, et al. . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2022. Diabetes Care. 2022;63:S125–S143. doi: 10.2337/dc22-S009 - PubMed
    1. Charbonnel B, Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Shih WJ, Liu J, Pong A, Gantz I, et al.. 783-P: Cardiorenal outcomes with ertugliflozin by baseline (BL) glucose-lowering agent (GLA): an analysis from VERTIS CV. Diabetes. 2021;70(suppl 1):783-P. doi: 10.2337/db21-783-P
    1. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al.. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–1435. doi: 10.1056/NEJMoa2004967 - PubMed
    1. Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, et al.. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64:1256–1267. doi: 10.1007/s00125-021-05407-5 - PMC - PubMed

MeSH terms